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Abstract
Previous research has indicated that allosteric interactions across the dimer
interface of b1-adrenoceptors may be responsible for a secondary low affinity
binding conformation. Here we have investigated the potential for probe
dependence, in the determination of antagonist pKi values at the human
b1-adenoceptor, which may result from such allosterism interactions. Three flu-
orescent b1-adrenoceptor ligands were used to investigate this using biolumi-
nescence energy transfer (BRET) between the receptor-bound fluorescent ligand
and the N-terminal NanoLuc tag of a human b1-adrenoceptor expressed in
HEK 293 cells (NanoBRET). This proximity assay showed high-affinity-specific
binding to the NanoLuc- b1-adrenoceptor with each of the three fluorescent
ligands yielding KD values of 87.1  10 nmol/L (n = 8), 38.1  12 nmol/L
(n = 7), 13.4  2 nmol/L (n = 14) for propranolol-Peg8-BY630, propranolol-
b(Ala-Ala)-BY630 and CGP-12177-TMR, respectively. Parallel radioligand-
binding studies with 3H-CGP12177 and TIRF microscopy, to monitor NanoLuc
bioluminescence, confirmed a high cell surface expression of the NanoLuc-
b1-adrenoceptor in HEK 293 cells (circa 1500 fmol.mg protein
1). Following a
1 h incubation with fluorescent ligands and b1-adrenoceptor competing antago-
nists, there were significant differences (P < 0.001) in the pKi values obtained
for CGP20712a and CGP 12177 with the different fluorescent ligands and
3H-CGP 12177. However, increasing the incubation time to 2 h removed these
significant differences. The data obtained show that the NanoBRET assay can
be applied successfully to study ligand-receptor interactions at the human
b1-adrenoceptor. However, the study also emphasizes the importance of ensur-
ing that both the fluorescent and competing ligands are in true equilibrium
before interpretations regarding probe dependence can be made.
Abbreviations
BRET, bioluminescence energy transfer; DMEM, Dulbecco’s modified Eagles med-
ium; FCS, fetal calf serum; HEK, human embryonic kidney; Nluc, NanoLuc; PBS,
phosphate-buffered saline.
Introduction
The human b1-adrenoceptor appears to exist in two
active conformations (Kaumann et al. 2001; Kaumann
and Molenaar 2008; Pak and Fishman 1996; Granneman
2001; Baker et al. 2003). One of these is a classical orthos-
teric-binding site via which endogenous ligands, such as
adrenaline and noradrenaline, mediate their agonist
effects. The actions of agonists at this site are potently
and competitively antagonized by b-blockers such as CGP
20712A, CGP 12177, and propranolol (Baker et al. 2003;
Baker 2005; Lowe et al. 2002; Joseph et al. 2004a). How-
ever, at much higher concentrations than required to
occupy the orthosteric site, CGP 12177 (Staehelin et al.
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1983) is able to produce an agonist response that is effec-
tively resistant to b-blocker antagonism at the concentra-
tions normally employed to prevent the binding of
agonists to the orthosteric site (Pak and Fishman 1996;
Baker et al. 2003; Baker 2005; Joseph et al. 2004a; Konkar
et al. 2000). The dissociation constants of classical b-adre-
noceptor antagonists are therefore one to two orders of
magnitude higher when determined from inhibition of
functional responses mediated by CGP 12177 at the b1-
adrenoceptor compared to those determined from antag-
onism of catecholamine responses (Molenaar et al. 2007;
Lowe et al. 2002; Baker et al. 2003; Baker 2005). Studies
in recombinant cell systems and cardiac tissue isolated
from b2- and b1-/b 2-adrenoceptor knockout mice have
confirmed that the second-site pharmacology of CGP
12177 is a direct consequence of its interaction with the
b1-adrenoceptor (Kaumann et al. 2001; Kaumann and
Molenaar 2008; Pak and Fishman 1996).
Site-directed mutagenesis studies have attempted to
isolate the regions of the b1-adrenoceptor responsible for
this second site pharmacology in CHO-K1 cells (Baker
et al. 2008, 2014; Joseph et al. 2004b). Baker et al. (2014)
have indicated that residues within the dimer interface
region in transmembrane domain (TM) 4 of the b1-adre-
noceptor may be responsible for the secondary b1-adreno-
ceptor conformation (Gherbi et al. 2015). In this
situation, negative cooperativity across the TM4-TM5 b1-
adrenoceptor homodimer interface may be responsible for
generating the low affinity pharmacology of the secondary
b1-adrenoceptor conformation (Gherbi et al. 2015) in a
manner analogous to that observed for the adenosine A3-
receptor (May et al. 2011; Corriden et al. 2014).
Recent studies with a fluorescent analog of CGP 12177
(BODIPY-TMR-CGP) have shown that at high concentra-
tions it can begin to label both conformations of the human
b1-adrenoceptor expressed in CHO-K1 cells (Gherbi et al.
2014, 2015). The availability of this ligand has made it pos-
sible to study the dynamics of ligand-receptor interactions
in living cells and provided evidence for negatively cooper-
ative interactions (Gherbi et al. 2014, 2015). Recently, we
developed an exquisitely sensitive proximity-based method
to monitor ligand-receptor interactions in living cells using
bioluminescence resonance energy transfer (BRET) (Stod-
dart et al. 2015). This used a recently described and extre-
mely bright luciferase NanoLuc (Hall et al. 2012) fused to
the N-terminus of different GPCRs expressed in HEK 293
cells in conjunction with red-shifted fluorescent ligands
(Stoddart et al. 2015). This NanoBRET approach was able
to show binding of fluorescent ligands to GPCRs in a highly
specific way. Furthermore, in the case of the adenosine A3-
receptor where a number of different fluorescent ligands
were available to probe this receptor, the study highlighted
the fact that binding affinities varied depending on the A3-
receptor fluorescent probe used (Stoddart et al. 2015).
These observations were in keeping with the known
allosterism observed across the A3-receptor homodimer
interface (May et al. 2011; Corriden et al. 2014; Stoddart
et al. 2015), and consistent with the expected probe depen-
dence for such allosteric interactions (May et al. 2007,
2010; Christopoulos and Kenakin 2002).
Here, we have investigated the potential for probe
dependence in the determination of antagonist pKi values
at the human b1-adenoceptor using three different fluo-
rescent b1-adrenoceptor ligands, in conjunction with a N-
terminal tagged NanoLuc human b1-adrenoceptor
expressed in HEK 293 cells.
Materials and Methods
cDNA constructs
To create the NL- b1-AR construct, NanoLuc (NL) was ini-
tially ligated into pcDNA3.1 containing the 5-HT receptor
membrane localization signal sequence (sig) using KpnI
and BamHI restriction enzymes, generating the sig-NL
plasmid. The b1 adrenoceptor with no start codon was then
ligated to the C-terminus of NL from pcDNA3.1 containing
SNAP-b1 (Gherbi et al. 2015) using BamHI and XbaI
restriction enzymes. The resulting fusion protein contained
a Gly-Ser linker between the Nluc open reading frame
(ORF) and the b1 ORF. The NanoLuc Histamine 1 receptor
construct (NL-H1) was made by removing the internal
BamHI site in the H1 receptor (in pcDNA3.1) by site-direc-
ted mutagenesis while maintaining the amino acid
sequence. This was then ligated into the sig-NL plasmid
with BamHI and XhoI restriction enzymes.
Materials
Propranolol-Peg8-BY630 (propranolol-peg8-BODIPY630/
650) and prop-b(Ala-Ala)-BY630 (propranolol-balanine-
balanine-X-BODIPY630/650) were obtained from CellAura
(Nottingham, UK). BODIPY-TMR-CGP (CGP-12177-
TMR) was purchased from Molecular Probes (Eugene,
OR). Propranolol, ICI 118551, CGP 12177, CGP 20712A,
and cimaterol were from Tocris (Bristol, UK). Isoprenaline
was purchased from Sigma-Aldrich (Gillingham, UK). The
NanoLuc substrate furimazine was obtained from Promega
(Southampton, UK). The radioligand 3H CGP 12177 was
obtained from PerkinElmer (Coventry, UK).
Cell lines
HEK 293 cells were maintained in Dulbecco’s modified
eagle medium (DMEM) containing 10% fetal calf serum
(FCS) and 2 mmol/L L-glutamine at 37°C in 5% CO2
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atmosphere. Mixed population NL-b1-AR and NL-H1
HEK 293 cell lines were generated using Fugene HD (Pro-
mega) according to the manufacturer’s instructions and
cells were then subjected to 1 mg/mL G418-selective pres-
sure for 2 weeks.
Radioligand-binding assays
Saturation- and competition-binding assays were per-
formed on stably transfected HEK NL- b1-AR cells. These
were seeded 24 h before experimentation in white Thermo
Scientific 96-well microplates. The medium was removed
from each well and replaced with serum-free media
(DMEM with 2 mmol/L L-glutamine), followed immedi-
ately by the required concentrations of 3H-CGP 12177
radioligand and competing compounds. For saturation-
binding assays, nonspecific binding was determined in the
presence of 10 lmol/L propranolol. The cells were incu-
bated for 2 h at 37°C, 5% CO2. The cells were washed twice
by the addition and subsequent removal of 200 lL phos-
phate-buffered saline (PBS). 200 lL microscint-20 (Perki-
nElmer) was added to each well, a white base applied to the
plate, and the plate sealed with a clear topseal heat seal
(PerkinElmer). The plates were counted on a Topcount
scintillation reader (PerkinElmer). Protein content of wells
was determined by the method of Lowry et al. (1951).
BRET NL-b1-AR receptor-ligand-binding
assays
Saturation- and competition-binding assays were per-
formed on stably transfected HEK 293 cells. Cells were
seeded 24 h before experimentation in white Thermo Sci-
entific 96-well microplates. The medium was removed
from each well and replaced with HEPES-buffered saline
solution (HBSS; 147 mmol/L NaCL, 24 mmol/L KCl,
1.3 mmol/L CaCl2, 1 mmol/L MgSO4, 10 mmol/L
HEPES, 2 mmol/L sodium pyruvate, 1.43 mmol/L
NaHCO3, 4.5 mmol/L D-glucose, pH 7.2–7.45) with the
relevant concentration of fluorescent ligand and, if neces-
sary, competing ligand. Nonspecific binding was deter-
mined with 10 lmol/L propranolol. Cells were then
incubated in the dark for 1 or 2 h at 37°C (no CO2). The
NanoLuc substrate furimazine (Promega) was then added
to each well at a final concentration of 10 lmol/L and
allowed to equilibrate for 5 min prior to reading. We
measured the luminescence signals at two different wave-
lengths using the PHERAstar FS plate reader (BMG Lab-
tech, UK) at room temperature. The filtered light from
each well was simultaneously measured using 460 nm
(80-nm bandpass) and >610 nm longpass filters. The
resulting raw BRET ratio was calculated by dividing the
>610 nm emission by the 460 nm emission.
Bioluminescence imaging of NL-b1-AR
Bioluniescence imaging experiments were performed to
determine the cellular localization of the NL-b1-AR fusion
protein. Imaging was performed using the Zeiss TIRF3
microscope equipped with a Photometrics Quantum EM
camera and a 209 EC Plan-Neofluar objective lens. No fil-
ter was used in these experiments, in order to maximize the
luminescence detected by the camera. HEK 293 cells were
seeded onto glass-bottom MatTek dishes (Ashland, MA)
and transiently transfected with the NL-b1-AR construct
24 h before experimentation using Fugene HD (Promega).
The medium was removed and replaced with HBSS at 37°C.
The luminescence of NL-b1-AR was captured as a single
10 sec exposure immediately after the addition of 10 lmol/
L furimazine. Following this a phase contrast image was
acquired of the cells with a 33 msec exposure time. All
images were acquired using the Zeiss Zen 2 software (Jena,
Germany). Image processing was performed with FIJI
software (Schindelin et al., 2012).
Data analysis
Data were presented and analyzed using Prism 6 software
(GraphPad).
Saturation-binding curves were simultaneously fitted to
obtain the total and nonspecific components using the
following equation:
Radioligand binding or BRET ratio
¼ Bmax  ½B½B þ KD þ ððM  ½BÞ þ CÞ
where Bmax is the maximal level of specific binding, [B] is
the concentration of fluorescent ligand or radioligand in
nmol/L, KD is the equilibrium dissociation constant in
nmol/L, M is the slope of the linear nonspecific binding
component, and C is the y-axis intercept.
Competition radioligand and NanoBRET data were fit-
ted using a one-site sigmoidal response curve given by
the following equation:
% uninhibited binding ¼ 100 ð100 ½A
nÞ
ð½An þ ICn50Þ
þ NS
where [A] is the concentration of competing drug, NS is
the nonspecific binding, n is the Hill coefficient, and IC50 is
the concentration of ligand required to inhibit 50% of the
specific binding of the radioligand or fluorescent ligand.
The IC50 values from competition-binding curves were
used to calculate the Ki of the unlabeled ligands using the
Cheng–Prusoff equation:
Ki ¼ IC50
1þ ½LKD
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where [L] is the concentration of fluorescent ligand or
radioligand in nmol/L, and KD is the dissociation con-
stant of the fluorescent ligand or radioligand in nmol/L.
The KD values used were obtained from the saturation-
binding experiments.
Statistical significance was determined by one-way anal-
ysis of variance (ANOVA, P < 0.05 considered signifi-
cant).
Results
3H-CGP 12177-binding experiments in NL-b1-
AR HEK 293 cells
Initial radioligand-binding experiments were performed
with the high affinity ligand 3H-CGP 12177 in HEK 293
cells stably expressing human b1-adrenoceptors contain-
ing an N-terminal Nanoluc luciferase fusion (NL-b1-
ARs). Saturation analysis showed clear specific binding
(Fig. 1; KD for
3H-CGP 12177 = 0.92  0.19 nmol/L;
n = 6) and a mean receptor expression level of
1581  350 pmol.mg protein1 (n = 6). The level of
nonspecific binding deduced in the presence of 10 lmol/L
propranolol was low across the concentrations of
3H-CGP 12177 employed (0–5 nmol/L; Fig. 1). Competi-
tion experiments with a range of b1-adrenoceptor agonists
and antagonists (Fig. 2A and B) fitted well to a simple
single mass action equilibrium model and allowed the
calculation of pKi values for the different inhibitors
(Table 1). As expected, the selective b1-adrenoceptor
antagonist CGP 20712A showed a much higher affinity
for the NL-b1-adrenoceptor (pKi: 7.92; Fig. 2A; Table 1)
than the b2-adrenoceptor-selective antagonist ICI 118551
(pKi 6.01; Table 1; Fig. 2A), although both values
were lower than those (8.81 and 6.52 for CGP 20712A
and ICI 118551, respectively) obtained in CHO cells
(Baker 2005).
Figure 1. 3H-CGP 12177 binding to HEK-NL-b1-AR cells showing
total 3H-CGP 12177 binding, nonspecific binding (obtained in the
presence of 10 lmol/L propranolol) and specific binding. Data points
are mean  SEM of quadruplicate determinations from a single
experiment. Similar data were obtained in six separate experiments.
Figure 2. Inhibition of 3H-CGP 12177 binding to HEK-NL-b1-AR cells
by (A) CGP 20712A, propranolol, ICI 118551, (B) isoprenaline,
cimaterol, CGP 12177. Nonspecific binding was defined in the
presence of 10 lmol/L propranolol. The concentration of 3H-CGP
12177 present in these experiments was 2.2 nmol/L. Data points are
triplicate determinations of mean  SEM and these single
experiments are representative of five separate experiments. Summary
data from the replicate experiments are provided in Table 1.
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Inhibition of 3H-CGP 12177 binding by three
different fluorescent b1-adrenoceptor
antagonists at the human b1-AR
Three different fluorescent b-AR ligands were used to
investigate binding to the b1-AR in this study: (1) Propra-
nolol-Peg8-BY630 (Baker et al. 2011); (2) Propranolol- b
(Ala-Ala)-BY630 (Stoddart et al. 2015), and (3) CGP-
12177-TMR (Gherbi et al. 2014). Initial studies were per-
formed to evaluate the ability of these ligands to inhibit
the binding of 3H-CGP 12177 (Fig. 3 and Table 2). The
pKi values obtained from these studies indicated that Pro-
pranolol-b(Ala-Ala)-BY630 and CGP-12177-TMR were
approximately an order of magnitude higher affinity than
Propranolol-Peg8-BY630 in HEK-293 cell expressing the
human b1-adrenoceptor (Table 2).
Binding characteristics of three fluorescent
b1-adrenoceptor antagonists at the human
b1-AR using NanoBRET
The successful expression of the NL-b1-AR on the surface
of HEK 293 cells is indicated by the radioligand-binding
studies with 3H-CGP-12177 (above), but also from imag-
ing of the Nanoluc bioluminescence using TIRF micro-
scopy (Fig. 4). In Figure 4, clear membrane-associated
luminescence can be seen at the single cell level. This cell
surface expression provided the opportunity to investigate
ligand binding of different fluorescent ligands using BRET
(NanoBRET) to report the proximity of the fluorescent
ligand to the NL-tagged b1-AR, as we have previously
shown for other receptors (Stoddart et al. 2015). All three
fluorescent ligands showed clear specific binding (as
determined by BRET) to the b1-AR (Figs. 5, 6). These
data provided estimates for the KD values of Propranolol-
Peg8-BY630 (87.1  10 nmol/L, n = 8; Figs. 5A, 6A),
Propranolol- b(Ala-Ala)-BY630 (38.1  12 nmol/L, n = 7;
Figs. 5B, 6B), and CGP-12177-TMR (13.4  2 nmol/L,
n = 14; Fig. 5C, 6C). The latter value is very similar to the
value (22.4 nmol/L; Gherbi et al. 2014) deduced with this
fluorescent probe at the wild-type b1-AR expressed in CHO
cells. To confirm that the interaction of the fluorescent
ligands with the b1-AR was receptor specific, we also evalu-
ated their ability to generate a BRET signal in HEK 293 cell
expressing an unrelated receptor, the human H1-receptor
with an N-terminal NanoLuc fusion (Fig. 7). The binding
of Propranolol-Peg8-BY630 (Fig. 7A), Propranolol- b(Ala-
Ala)-BY630 (Fig. 7B), and CGP-12177-TMR (Fig. 7C) to
the histamine H1-receptor showed an essentially linear
increase in BRET over a wide concentration range
(0–500 nmol/L) consistent with nonspecific (Fig. 7A and
C) or very low affinity binding (Fig. 7B).
Probe dependence of pKi values determine
for b1-AR agonists and antagonists
The availability of three different fluorescent ligands for
the b1-AR provided the opportunity to investigate
whether competition-binding experiments exhibited probe
dependence, and the extent to which the values obtained
for pKi differed from those obtained from radioligand-
binding experiments. Competition-binding experiments
were initially undertaken with the two fluorescent propra-
nolol derivatives that essentially only differ in the length
and composition of the linker between propranolol and
the BODIPY 630/650 fluorophore (Fig. 8). In both cases,
there was a reasonable agreement with the values
obtained from radioligand-binding experiments with 3H-
CGP 12177 (Fig. 8B and D). The slope of the linear
regression lines in Figures 8B and D were 0.87  0.08
Table 1. Binding affinities of competing ligands determined from inhibition of the specific binding of 0.9–2.5 nmol/L 3H-CGP 12177, 100 nmol/L
Propranolol-Peg8-BY630, 50 nmol/L Propranolol-b(Ala-Ala)-BY630 or 50 nmol/L CGP-12177-TMR in HEK 293 cells expressing a NanoLuc-tagged
human b1-adrenoceptor.
3H-CGP-12177
Propranolol-Peg8-
BY630
Propranolol-
b(Ala-Ala)-BY630 CGP-12177-TMR
pKi n pKi n pKi n pKi n
Isoprenaline** 6.18  0.07 5 6.72  0.12 7 5.95  0.09 8 6.56  0.05 5
Cimaterol* 6.03  0.05 5 6.44  0.11 7 5.84  0.22 8 6.34  0.19 5
CGP 12177** 8.76  0.09 5 8.67  0.05 7 8.15  0.10 8 8.93  0.07 5
CGP 20712A** 7.92  0.11 5 8.52  0.09 7 7.84  0.07 8 8.85  0.19 5
Propranolol 7.92  0.09 5 8.11  0.12 5 7.77  0.21 5 7.80  0.08 5
ICI 118551 6.01  0.13 5 6.55  0.19 5 6.18  0.22 5 6.51  0.05 5
Incubations were for 1 h. Values show mean  SEM obtained in n separate experiments. In each individual experiment triplicate determinations
were made for each experimental condition. pKi values were determined from IC50 values using the Cheng–Prusoff equation as described under
Methods. **,*pKi values obtained of competing ligand significantly differ between fluorescent/radioactive probes (**P < 0.001; *P < 0.05; One-
way ANOVA).
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(R2 = 0.97; y intercept = 1.38  0.56) and 0.87  0.08
(R2 = 0.97; y intercept = 0.73  0.60), respectively. How-
ever, a comparison of the pKi values obtained with the
two fluorescent propranolol derivatives revealed a trend
to higher values obtained with Propranolol-Peg8-BY630
relative to Propranolol-b(Ala-Ala)-BY630 (Table 1).
Comparable higher pKi values were also obtained with
CGP-12177-TMR (Fig. 9; Table 1). However, although
the correlation between pKi values obtained with
3H-CGP
12177 and CGP-12177-TMR was similar to the other
comparisons (Fig. 9C; 0.95  0.14; y intercept
0.74  1.00; R2 = 0.92) the values obtained with CGP
20712A differed by an order of magnitude. A compar-
ison of the pKi values obtained for each competing
antagonist ligand suggested that there were significant
Figure 3. Inhibition of 3H-CGP 12177 binding to HEK-NL-b1-AR cells
by propranolol-Peg8-BY630, propranolol-b(Ala-Ala)-BY630 and CGP-
12177-TMR. Nonspecific binding was defined in the presence of
10 lmol/L propranolol. The concentration of 3H-CGP 12177 present
in these experiments was 0.9–2.5 nmol/L. Data points in (A) are
mean  SEM of triplicate determinations in a single representative
experiment. (B) Inhibition of specific 3H-CGP 12177 binding by each
fluorescent ligand expressed as a percentage of the specific binding
obtained in the absence of inhibitor. Data points in (B) are
mean  SEM of six (propranolol-Peg8-BY630), seven (propranolol-b
(Ala-Ala)-BY630), and five (CGP-12177-TMR) separate experiments.
Summary data from the replicate experiments are provided in Table 2.
Table 2. Binding affinities of three fluorescent ligands determined
from inhibition of the specific binding of 0.9–2.5 nmol/L 3H-CGP
12177 and from the saturation of Prop-peg8-BY630, Prop- b(Ala-Ala)-
BY630, or CGP-12177-TMR in HEK 293 cells expressing a NanoLuc-
tagged human b1-adrenoceptor.
Fluorescent
Ligand
Radioligand 1 h NanoBRET 2 h NanoBRET
pKi n pKd n pKd n
Prop-peg8-
BY630
6.17  0.15 6 7.06  0.12 8 6.18  0.22 5
Prop-
b(Ala-Ala)
-BY630
7.26  0.09 7 7.23  0.12 7 7.86  0.14 5
CGP-12177-
TMR
7.55  0.15 5 7.87  0.06 14 7.72  0.10 5
Values show mean  SEM obtained in n separate experiments. In
each individual experiment triplicate determinations were made for
each experimental condition. pKi values were determined from IC50
values using the Cheng–Prusoff equation as described under Methods.
pKd values were determined from NanoBRET saturation fluorescent
ligand-binding analysis performed over 1 h or 2 h incubation. Radioli-
gand-binding studies were performed over 2 h incubations. BRET, bio-
luminescence energy transfer.
Figure 4. Image of HEK 293 cells transiently transfected with NL-b1-
AR showing clear plasma membrane distribution of the fusion
protein. This single 10 sec exposure image was taken immediately
after the addition of 10 lmol/L furimazine and is representative of
five separate experiments. Scale bar is 20 lm.
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probe-dependent differences between them (Fig. 10). In
the case of CGP20712A and CGP 12177, the differences
were highly significant (P < 0.001; one-way ANOVA;
Fig. 10A).
Impact of incubation time
One clear difference between the experimental conditions
used for fluorescent ligand-binding (1 h incubation) and
radioligand-binding (2 h incubation) studies was incuba-
tion time. The initial choice of 1 h for incubation with
fluorescent ligands was to limit the potential for uptake
of the more lipophilic ligands into the cells, which has
been previously observed to increase the nonspecific
binding determined in fluorescence intensity measure-
ments (Baker et al. 2011; Gherbi et al. 2014). To explore
the potential for the shorter incubation time to be a
confounding factor due to differences in the ligand-
binding kinetics of the ligands used (both fluorescent
and competing ligands), we repeated the fluorescent
ligand experiments with CGP 20712A and CGP 12177
as competing drugs over 2 h incubations. Analysis of
these data indicated that there were no significant differ-
ences between pKi values obtained with different fluores-
cent ligands or 3H-CGP12177 following 2 h incubation
(Table 3, Fig. 10B). Here, the IC50 values for CGP
Figure 5. NanoBRET signal obtained from HEK 293 NL-b1-AR cells incubated for 1 h with increasing concentrations of (A) Propranolol-Peg8-
BY630 (B) Propranolol-b(Ala-Ala)-BY630, or (C) CGP-12177-TMR. Nonspecific binding was determined in the presence of 10 lmol/L propranolol.
Data points are mean  SEM of triplicate determinations from a single experiment. These single experiments are representative of (A) eight, (B)
seven, and (C) fourteen separate experiments. Where not seen, error bars are within the symbol. BRET, bioluminescence energy transfer.
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Figure 6. Normalized saturation-binding curves of the specific
binding of (A) Propranolol-Peg8-BY630 (B) Propranolol-b(Ala-Ala)-
BY630, or (C) CGP-12177-TMR. Data points are mean  SEM of
eight (propranolol-Peg8-BY630), seven (propranolol- b(Ala-Ala)-
BY630), and fourteen (CGP-12177-TMR) separate experiments. Values
have been normalized to the specific binding obtained at the highest
concentration of each fluorescent ligand in each separate experiment.
Nonspecific binding was determined in the presence of 10 lmol/L
propranolol and subtracted from the total binding values to obtain
specific binding levels in each individual experiment. Summary data
for the pKd values obtained in each replicate experiment are provided
in Table 2.
Figure 7. NanoBRET signal obtained from HEK 293 cells expressing
an NLuc-tagged histamine H1-receptor incubated for 1 h with
increasing concentrations of (A) Propranolol-Peg8-BY630, (B)
Propranolol-b(Ala-Ala)-BY630, (C) CGP-12177-TMR. Nonspecific
binding was determined in the presence of 10 lmol/L mepyramine.
Data points are mean  SEM from triplicate determinations in a
single representative experiment. These single experiments are
representative of five separate experiments. BRET, bioluminescence
energy transfer.
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12177 and CGP 20712A were corrected for the presence
of the fluorescent ligand using the Cheng–Prusoff equa-
tion and the pKd values for the three fluorescent ligands
obtained from saturation analysis at 2 h incubation
(Table 2).
Discussion and Conclusions
This study has confirmed that the recently described
NanoBRET proximity assay for the study of ligand
binding to cell surface GPCRs (Stoddart et al. 2015) can
be applied to the human b1-adrenoceptor expressed in
HEK 293 cells. The presence of the NanoLuc tag on the
N-terminus of the b1-adrenoceptor did not prevent a
good level of cell surface expression of the receptor, as
determined by both single cell bioluminescence imaging
of the NanoLuc tag and whole-cell radioligand-binding
studies with 3H-CGP 12177 (circa 1500 fmol. mg pro-
tein1). Radioligand-binding studies with 3H-CGP 12177
also confirmed that the NLuc- b1-adrenoceptor had high
Figure 8. NanoBRET signal from NL- b1-AR cells treated with (A–B) 100 nmol/L Propranolol-Peg8-BY630, (C–D) 50 nmol/L Propranolol- b(Ala-
Ala)-BY630 and increasing concentrations of (A) CGP 20712A, ICI 118551, CGP 12177 or (C) CGP 20712A, CGP 12177. (B, D) Regression plots
comparing the pKi obtained from NanoBRET binding to those obtained using radioligand binding. Data points are combined mean  SEM from
(A–B) seven and (C–D) eight separate experiments. Exceptions are propranolol and ICI 118551 in both figures where data represent mean  SEM
from five separate experiments. BRET, bioluminescence energy transfer.
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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affinity for the b1-adrenoceptor-selective ligand CGP
20712A and low affinity for the b2-adrenceptor antagonist
ICI 118551.
Three different fluorescent b-AR ligands were used to
investigate binding to the b1-AR in this study: (1) Propra-
nolol-Peg8-BY630 (Baker et al. 2011); (2) Propranolol- b
(Ala-Ala)-BY630 (Stoddart et al. 2015), and (3) CGP-
12177-TMR (Gherbi et al. 2014). Only one of these has
been previously used in a NanoBRET ligand-binding
assay, and that was to study binding to a NanoLuc-tagged
Figure 9. NanoBRET signal from NL-b1-AR cells treated with 50 nmol/L
CGP-12177-TMR and increasing concentrations of (A) isoprenaline,
cimaterol, CGP-12177 (B) propranolol, CGP 20712A, ICI 118551. Data
points are expressed as a % of the specific binding of CGP-12177-TMR
obtained (in the absence of inhibitor) in each individual experiment and
represent the mean  SEM from five separate experiments. Nonspecific
binding was determined in the presence of 10 lmol/L propranolol. (C)
Regression plot comparing the pKi obtained from the NanoBRET
experiments in (A–B) to pKi obtained with radioligand-binding studies.
BRET, bioluminescence energy transfer.
Figure 10. A comparison of pKi values obtained at the NL-tagged
b1-adrenoceptor using three different fluorescent b1-adrenoceptor
ligands (Propranolol-Peg8-BY630, Propranolol-b(Ala-Ala)-BY630, or
CGP-12177-TMR) and 3H-CGP 12177. Incubation with fluorescent
ligands was for either 1 h (A) or 2 h (B). pKi values were taken from
Table 1 (A) or Table 3 (B) (see tables for SEMs and n numbers). **,
*pKi values obtained for competing ligand significantly differ between
fluorescent/radioactive probes (**P < 0.001; One-way ANOVA).
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human b2-adrenoceptor (Stoddart et al. 2015). All three
ligands showed good receptor-specific binding to the
human b1-adrenoceptor in HEK 293 cells. Their rank
order of affinity (KD values) was: CGP-12177-TMR
(13.4 nmol/L), propranolol- b(Ala-Ala)-BY630 (38 nmol/
L), and propranolol-Peg8-BY630 (87.1 nmol/L). Interest-
ingly, this proximity-based assay allowed ligand binding
to be monitored over a wide concentration range and
nonspecific binding was not excessive. Nonspecific bind-
ing was greatest for propranolol- b(Ala-Ala)-BY630 and
propranolol-Peg8-BY630. This is likely to be a conse-
quence of partitioning in the membrane of these more
lipophilic ligands in close proximity to the NLuc tag on
the b1-adrenoceptor.
To investigate further whether these fluorescent ligands
could generate a BRET signal with the N-terminal NLuc-
tag of the b1-adrenoceptor from nonspecific partitioning in
the adjacent membrane (i.e., in close proximity to the
receptor), we studied an unrelated NLuc-tagged GPCR,
namely the histamine H1-receptor. Interestingly, both pro-
pranolol- b(Ala-Ala)-BY630 and propranolol-Peg8-BY630
generated a linear concentration-dependent increase in
energy transfer from the NLuc of the H1-receptor to the
fluorescent ligand that was consistent with some compo-
nent of the BRET signal being due to the fluorescent ligand
in the adjacent plasma membrane. In contrast, when CGP-
12177-TMR was used as the fluorescent ligand there was no
concentration-dependent increase in nonspecific binding.
In the case of both propranolol-Peg8-BY630 and CGP-
12177-TMR, the binding obtained was not inhibited by
10 lmol/L mepyramine, while any effect on propranolol- b
(Ala-Ala)-BY630 was marginal, confirming that it was pre-
dominately nonspecific in nature.
The specific binding of each fluorescent ligand to the
NL-b1-adrenoceptor was antagonized by a range of antago-
nists in a manner consistent with that expected of a specific
b1-adrenoceptor interaction. However, closer inspection of
the pKi values obtained for individual competing antago-
nists indicated that some of them varied significantly
depending on the particular fluorescent ligand used as the
probe (Fig. 10A). This was particularly the case for CGP
12177 and CGP 20712a (Fig. 10A). One clear difference
between the experimental conditions used for fluorescent
ligand binding and those for radioligand-binding studies
was incubation time. The initial choice of 1 h for incuba-
tion with fluorescent ligands was designed to limit the
potential for uptake of the more lipophilic ligands into the
cells, which tends to increase the nonspecific binding deter-
mined in fluorescence intensity measurements (Baker et al.
2011; Gherbi et al. 2014; Rose et al. 2012). However, if the
incubation times used for the various assays are not suffi-
ciently long to achieve equilibrium, then over- or under-
estimates of pKi values for certain competing ligands may
be obtained (Motulsky and Mahan 1984). This may be
compounded if the probe or competing drugs are lipophilic
and their rate of achieving equilibrium is delayed by mem-
brane-binding interactions (Sykes et al. 2014; Vauquelin
and Charlton 2010; Vauquelin 2010).
Extending the incubation time for the NanoBRET com-
petition assay to 2 h provided consistent measurements of
ligand binding with all three fluorescent ligands. Further-
more, in keeping with the above hypothesis, extension of
the fluorescent ligand-binding incubation time from 1 h
to 2 h removed any significant probe-dependent differ-
ences in the observed pKi values obtained (Fig. 10B).
These data suggest that at the concentrations of fluores-
cent ligand employed here there is no evidence of probe
dependence. The data obtained at the two incubation
times also emphasize the importance of ensuring that
both the fluorescent and competing ligands are in true
equilibrium before interpretations regarding probe depen-
dence can be made.
In summary, we have shown here that a NanoBRET
proximity assay can be used to undertake a detailed char-
acterization of the ligand-binding characteristics of three
different fluorescent ligands at the human b1-adrenocep-
tor expressed in living HEK 293 cells. Provided that
the incubation time was sufficiently long to achieve
equilibrium, the pKi values obtained for four different
b-adrenoceptor antagonists did not provide any evidence
Table 3. Binding affinities of competing ligands determined from inhibition of the specific binding of a 2-h incubation with 0.9–2.5 nmol/L 3H-
CGP 12177, 100 nmol/L Propranolol-Peg8-BY630, 50 nmol/L Propranolol- b(Ala-Ala)-BY630, or 50 nmol/L CGP-12177-TMR in HEK 293 cells
expressing a NanoLuc-tagged human b1-adrenoceptor.
3H-CGP-12177
Propranolol-Peg8-
BY630
Propranolol-b(Ala-Ala)-
BY630 CGP-12177-TMR
pKi n pKi n pKi n pKi n
CGP 12177 8.76  0.09 5 8.51  0.13 9 8.84  0.14 5 8.51  0.10 9
CGP 20712A 7.92  0.11 5 8.17  0.16 7 8.32  0.16 5 7.99  0.10 8
Values show mean  SEM obtained in n separate experiments. In each individual experiment triplicate determinations were made for each experi-
mental condition. pKi values were determined from IC50 values using the Cheng–Prusoff equation as described under Methods. pKi values
obtained of competing ligand do not significantly differ between fluorescent/radioactive probes (One-way ANOVA).
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for probe dependence at the human b1-adrenoceptor.
Further studies will be required using mutagenesis and
kinetic approaches to determine whether there is alloster-
ism across dimer interfaces involving the b1-adrenoceptor
in HEK 293 cells similar to that observed previously in
CHO-K1 cells (Gherbi et al. 2015).
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